focus -WSS

focus

author：hotspot 2025-10-02 22:28:11 - browse：51

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Making the case for fair compensation in clinical trials

WSS

Questions and answers about ramping up H5N1 bird flu vaccine

FDA poised to publish guidelines for clinical trial diversity

Listen: A conversation with researcher Kevin Esvelt on biosecurity

The cancer stories no one wants to hear

Chris Christie meets with Zelenskyy during Ukraine trip

The a glaring gap in research on serious mental illness and primary care

hotspot

focus

knowledge

Medicare details structure of new drug price negotiation program

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Supreme Court strikes down use of affirmative action

Alnylam reports growth in sales of rare disease treatments

Virginia high school admissions case could be legal follow

CDC recommends RSV monoclonal antibody for infants

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Scrutiny of post

In Memoriam: Notable people who died in 2023

Eyeing GLP

leisure time

Bird flu surveillance in wastewater gets boost from consortium

As a primary care physician, here's how I hope to partner with AI

'Null' research findings aren't empty of meaning. Let's publish them

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Alnylam reports growth in sales of rare disease treatments

It costs an awful lot of money to give away a kidney

focus

knowledge

hotspot

leisure time